AI-powered precision drug dosing can boost outcomes and cost efficiency

Shivrat Chhabra is CEO of Dosis, a company that offers an artificial intelligence-powered personalized dosing platform used by dialysis providers to manage chronic drug regimens. Dosis developed the Strategic Anemia Advisor, an AI-based dosing platform for patients with chronic anemia. Chhabra provides the following statistics for provider organizations using his company's anemia advisor: Healthcare IT News interviewed Chhabra to get his thoughts on whether AI precision dosing can be the standard of care for chronic disease management, why AI dosing is particularly impactful in the dosing of drugs used to manage chronic conditions, and the downsides of relying on one-size-fits-all drug dose recommendations from manufacturers and the FDA. Q: Why should AI-powered precision drug dosing be the standard of care for chronic disease management? A: Drug dosing driven by AI is becoming more prevalent in many areas of medicine, such as dialysis, cancer and transplant medicine.